Acurx Pharmaceuticals Reports Full Year and Q4 Results, Provides Business Update

Company advancing ibezapolstat clinical trials for treatment and prevention of recurrent C. difficile infection

Mar. 13, 2026 at 4:01pm

Got story updates? Submit your updates here. ›

Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced financial and operational results for the full year and fourth quarter of 2025. Highlights include receiving $1.4 million in warrant exercises, presenting at IDWeek, publishing research in Nature Communications, and receiving a new patent. The company is launching a clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, with the potential to shift the treatment paradigm.

Why it matters

Acurx's lead antibiotic candidate, ibezapolstat, is preparing for Phase 3 clinical trials to treat C. difficile infection (CDI), which the CDC has designated as an urgent threat. The company's new clinical trial program in recurrent CDI aims to demonstrate ibezapolstat's potential to be the first agent to successfully treat and prevent recurrent CDI, an area of high unmet medical need.

The details

In the fourth quarter of 2025, Acurx received $1.4 million from warrant exercises, presented an update on ibezapolstat at IDWeek, published research in Nature Communications, and received a new patent. The company is now launching a clinical trial program for ibezapolstat in patients with recurrent CDI, starting with an open-label pilot trial. This will inform a planned Phase 3 registration trial in recurrent CDI, with the goal of seeking FDA approval for both treatment and prevention of recurrent CDI.

  • In October 2025, the company received $1.4 million from the exercise of 170,068 Series F Warrants.
  • In October 2025, Acurx presented an update on ibezapolstat at IDWeek in Atlanta.
  • In November 2025, the Nature Communications journal published results from Acurx's collaboration with Leiden University Medical Center.
  • In February 2026, the USPTO granted a new patent for Acurx's Pol IIIC inhibitors, extending to December 2039.
  • On March 9, 2026, Acurx announced the launch of a clinical trial program for ibezapolstat in patients with recurrent CDI.

The players

Acurx Pharmaceuticals, Inc.

A late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, including C. difficile infection.

Dr. Michael Silverman

Acurx's Medical Director, who presented an update on ibezapolstat at IDWeek.

Dr. Kevin Garey

Professor and Chair of the University of Houston College of Pharmacy, and the Principal Investigator for the microbiology and microbiome aspects of the ibezapolstat clinical trial program.

Leiden University Medical Center (LUMC)

Acurx's scientific collaborator, whose research on ibezapolstat was published in Nature Communications.

U.S. Food and Drug Administration (FDA)

The regulatory agency that has designated ibezapolstat as a Qualified Infectious Disease Product (QIDP) and granted it Fast Track designation for the treatment of C. difficile infection.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.